Payment overview · 2025
General Payments
$1,584.32
79 reported records · 18 companies
Healthcare provider profile · identity verified
Han Suk Koh, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · SAYRE, PA · NPI 1720057326
Verified facts
What the public records show
CMS Open Payments records show Han Suk Koh, MD received $1,584.32 in general payments during 2025 across 79 reported records.
Eisai Inc. accounted for 13.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Nurtec Odt, Ubrelvy, Zeposia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ubrelvy by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Sunosi as an associated drug or biological on 19758 records involving 6305 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Sunosi by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 9581 records involving 2490 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Zeposia by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ingrezza by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Eisai Inc. | Unresolved — no canonical attribution shown | $212.23 | 13.4% | 5 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $182.07 | 11.5% | 30 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $162.05 | 10.2% | 13 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $118.02 | 7.5% | 7 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $113.98 | 7.2% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $102.98 | 6.5% | 3 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $83.79 | 5.3% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $82.87 | 5.2% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $74.16 | 4.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.28 | 3.9% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $57.16 | 3.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.78 | 3.5% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $54.99 | 3.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $53.46 | 3.4% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $52.41 | 3.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.06 | 3.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $37.45 | 2.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $26.58 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,529.33 | 78 |
| Education | $54.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $212.23 | 5 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $182.07 | 30 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $162.05 | 13 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $123.42 | 12 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $118.02 | 7 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $113.98 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $102.98 | 3 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $82.87 | 4 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $74.16 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $59.74 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $57.16 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $55.78 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $53.46 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $52.41 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $52.06 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.91 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $37.45 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $36.03 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $26.58 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $24.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 39 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZEPOSIA zeposia |
2025 | Zeposia | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Sunosi open payments reported associated product |
CMS Open Payments — General Payments 19758 supporting records · 6305 recipient NPIs · example record 1235293059 |
Sunosi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 9581 supporting records · 2490 recipient NPIs · example record 1184377823 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
39 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 285 | 52 |
| Levetiracetam | Levetiracetam | 261 | 53 |
| Donepezil Hcl | Donepezil Hcl | 257 | 57 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 246 | 55 |
| Memantine Hcl | Memantine Hcl | 199 | 41 |
| Topiramate | Topiramate | 160 | 40 |
| Kesimpta Pen | Ofatumumab | 112 | suppressed |
| Pregabalin | Pregabalin | 107 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 27 |
| Baclofen | Baclofen | 88 | 24 |
| Nortriptyline Hcl | Nortriptyline Hcl | 86 | 20 |
| Primidone | Primidone | 82 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 82 | 17 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 79 | 20 |
| Mirtazapine | Mirtazapine | 78 | 22 |
| Divalproex Sodium | Divalproex Sodium | 73 | 12 |
| Modafinil | Modafinil | 73 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 72 | 16 |
| Clonazepam | Clonazepam | 71 | 13 |
| Amantadine | Amantadine Hcl | 68 | 22 |
| Oxcarbazepine | Oxcarbazepine | 57 | suppressed |
| Lamotrigine | Lamotrigine | 55 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 55 | 16 |
| Benztropine Mesylate | Benztropine Mesylate | 50 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 39 | 15 |
| Clobazam | Clobazam | 37 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 37 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 37 | suppressed |
| Armodafinil | Armodafinil | 34 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 30 | suppressed |
| Rivastigmine | Rivastigmine | 30 | suppressed |
| Zeposia | Ozanimod Hydrochloride | 30 | suppressed |
| Xcopri | Cenobamate | 29 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 27 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 25 | suppressed |
| Carbamazepine Er | Carbamazepine | 25 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Neupro | Rotigotine | 23 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 22 | suppressed |
| Teriflunomide | Teriflunomide | 22 | suppressed |
| Zonisamide | Zonisamide | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 20 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Diazepam | Diazepam | 19 | 15 |
| Entacapone | Entacapone | 19 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 18 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Ubrelvy | Ubrogepant | 18 | suppressed |
| Dalfampridine Er | Dalfampridine | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 16 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 16 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 16 | suppressed |
| Azathioprine | Azathioprine | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 12 | suppressed |
| Copaxone | Glatiramer Acetate | 12 | suppressed |
| Droxidopa | Droxidopa | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Topiramate Er | Topiramate | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Savella | Milnacipran Hcl | 11 | suppressed |
| Sunosi | Solriamfetol Hcl | 11 | suppressed |
| Tecfidera | Dimethyl Fumarate | 11 | suppressed |
| Tegretol Xr | Carbamazepine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,584.32 · 79 records | Eisai Inc. | BOTOX, BRIUMVI, EPIDIOLEX, INGREZZA, INSPIRE, KESIMPTA, KISUNLA, Leqembi, NURTEC ODT, PONVORY, QULIPTA, Rystiggo, Symbravo, UBRELVY, ULTOMIRIS, VYEPTI, VYVGART, VYVGART HYTRULO, WAINUA, ZAVZPRET, ZEPOSIA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error